drugset / Trial / NCT05432882
CD19/22 Bi-specific CAR-T Cell Therapy
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the feasibility, safety and efficacy of anti-CD19/22 bi-specific CAR-T cell therapy in patients with CD19 and/or CD22 positive B cell malignancies. Another goal of the study is to learn more about the safety and function of the anti-CD19/22 bi-specific CAR-T cells and their persistency in patients.
Timeline
- Start
- 2026-06-01
- Primary completion
- 2029-12-31
- Completion
- 2030-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | bi-4SCAR CD19/22 T cells | Cell therapy | 1e+06 cells/kg | Intravenous |